NYSEMKT: LCTXLineage Cell Therapeutics Revenue
Lineage Cell Therapeutics revenue was $9.50M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $2.9M, down 24.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, LCTX annual revenue was $9.5M, with 6.2% growth year-over-year.
LCTX past revenue growth
How has LCTX's revenue growth performed historically?
Company
6.19%
Industry
437.31%
Market
20.27%
LCTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
LCTX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
LCTX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
LCTX revenue history
Current Revenue
$9.5M
Current Earnings
-$18.6M
Current Profit Margin
-195.9%
Be the first to know when LCTX announces revenue.
LCTX Revenue History By Year
| LCTX Yearly Revenue | LCTX Revenue | LCTX Change | LCTX Revenue Growth |
|---|---|---|---|
| 2024-12-31 | $9.50M | $554.00k | +6.19% |
| 2023-12-31 | $8.95M | -$5.76M | -39.16% |
| 2022-12-31 | $14.70M | $10.36M | +238.70% |
| 2021-12-31 | $4.34M | $2.52M | +137.73% |
| 2020-12-31 | $1.83M | -$1.69M | -48.05% |
| 2019-12-31 | $3.52M | -$1.47M | -29.53% |
| 2018-12-31 | $4.99M | $1.53M | +44.25% |
| 2017-12-31 | $3.46M | -$2.47M | -41.62% |
| 2016-12-31 | $5.92M | -$1.11M | -15.82% |
| 2015-12-31 | $7.04M | $1.79M | +34.17% |
| 2014-12-31 | $5.24M | $810.00k | +18.27% |
| 2013-12-31 | $4.43M | $518.67k | +13.25% |
| 2012-12-31 | $3.92M | -$518.83k | -11.70% |
| 2011-12-31 | $4.43M | $726.14k | +19.58% |
| 2010-12-31 | $3.71M | $1.78M | +92.61% |
| 2009-12-31 | $1.93M | $421.38k | +28.02% |
| 2008-12-31 | $1.50M | $457.67k | +43.75% |
| 2007-12-31 | $1.05M | -$115.89k | -9.97% |
| 2006-12-31 | $1.16M | $258.82k | +28.66% |
| 2005-12-31 | $903.20k | $214.82k | +31.21% |
| 2004-12-31 | $688.38k | $131.96k | +23.71% |
| 2003-12-31 | $556.42k | $169.40k | +43.77% |
| 2002-12-31 | $387.02k | $235.10k | +154.76% |
| 2001-12-31 | $151.92k | $99.43k | +189.41% |
| 2000-12-31 | $52.49k | -$985.01k | -94.94% |
| 1999-12-31 | $1.04M | -$112.50k | -9.78% |
| 1998-06-30 | $1.15M | $1.09M | +1,740.00% |
| 1997-12-31 | $62.50k | N/A | N/A |
| 1996-12-31 | $0.00 | N/A | N/A |
| 1995-06-30 | $0.00 | N/A | N/A |
Lineage Cell Therapeutics Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.